Webinar Addresses 3D Cell-Based Models for Regenerative Medicine
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.
Two-dimensional (2D) cell cultures have provided a number of breakthroughs for understanding human tissues and diseases, as well as for discovering and testing new drugs. However, 2D cell cultures have limitations, such as limited cell-cell and cell-matrix contacts, flat cellular morphologies and a lack of realistic mass transfer gradients. As a result, technologies that facilitate growing cells in three-dimensional (3D) configurations have been developed to make cellular behaviors in vitro better resemble the body.
In this recorded webinar, Dr Katz assesses the impact on the physiological relevance of in vitro cell-based models using traditional ECM proteins, alvetex scaffolds and low adhesion plates in drug discovery and disease modeling applications. Highlighting examples including oncology and stem cell culture, Dr Katz demonstrates how the different 3D technologies that AMSBIO provides can help researchers to successfully perform the applications they need. Drug discovery considerations such as suitability for high-throughput screening are discussed in detail.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...